title: Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
abstract: BACKGROUND
  A 63-year-old woman with chronic myeloid leukemia (CML) received treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic response that was repetitively documented, IFN-α treatment was stopped. Despite maintenance of a complete cytogenetic response, a progressive rise of the BCR-ABL1 transcript was detected and loss of major molecular response occurred about 2 years after stopping IFN-α therapy. Disease remained at molecular level.
  
  
  METHODS
  Peripheral blood quantitative real-time PCR every 3 months and periodical bone marrow aspirate were performed to monitor disease.
  
  
  METHODS
  Chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy.
  
  
  RESULTS
  The patient was treated with a target immune approach receiving a therapeutic vaccine that consisted of an immunogenic 25-mer b2a2 breakpoint-derived peptide (CMLb2a2-25) with binding properties for several HLA-DR molecules. After nine boosts of vaccine the patient developed an adequate b2a2-25 peptide-specific CD4(+) T-cell response and BCR-ABL1 transcript started to decline in peripheral blood. No hematological or extrahematological effects were documented during therapy. At the last evaluation, 39 months since vaccinations commenced, the patient is in complete molecular response with an undetectable level of BCR-ABL1 transcript both in peripheral blood and in bone marrow and she continues to receive boosts of vaccine every 3 months as the only treatment.
authors.affiliation: Hematology and Transplants, University of Siena and AOUS, Viale Bracci 16, 53100 Siena, Italy. bocchia@unisi.it
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Lara
authors.initials: L
authors.lastname: Aprile
authors.forename: Micaela
authors.initials: M
authors.lastname: Ippoliti
authors.forename: Rosaria
authors.initials: R
authors.lastname: Crupi
authors.forename: Michela
authors.initials: M
authors.lastname: Rondoni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Francesco
authors.initials: F
authors.lastname: Lauria
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000097:blood*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1429-35
references.pmid: 20142590
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):535-43
references.pmid: 19652654
references.citation: Lancet. 2007 Jul 28;370(9584):342-50
references.pmid: 17662883
references.citation: Blood. 2009 Oct 15;114(16):3376-81
references.pmid: 19661271
references.citation: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references.pmid: 18519952
references.citation: Cancer. 2009 Sep 1;115(17):3924-34
references.pmid: 19536894
references.citation: Blood. 2008 Feb 15;111(4):1774-80
references.pmid: 18055868
references.citation: Blood. 2001 Nov 15;98(10):3074-81
references.pmid: 11698293
references.citation: Blood. 2007 Jan 1;109(1):58-60
references.pmid: 16973963
references.citation: Leukemia. 2009 Jun;23(6):1054-61
references.pmid: 19282833
references.citation: Leukemia. 2007 Nov;21(11):2287-95
references.pmid: 17637811
references.citation: Ann Hematol. 2002;81 Suppl 2:S45-6
references.pmid: 12611074
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Lancet. 2005 Feb 19-25;365(9460):657-62
references.pmid: 15721470
references.citation: Leukemia. 2008 Jan;22(1):96-102
references.pmid: 17943168